Migalastat
Ended Awarded Last action
- Contract number
- 36C26126F0156
- Awardee
-
Amicus Therapeutics US, LLC UEI KLJFGENKMD89
- Awarding agency
-
Veterans Integrated Service Network 21
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $22,840
Award facts
- Contract value 100% obligated
- $22,839.61 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Philadelphia, PA 19104, USA
Award details come from SAM.gov/FPDS.
About this award
The Department of Veterans Affairs, Veterans Integrated Service Network 21 (VISN 21), awarded a delivery order valued at $22,839.61 to Amicus Therapeutics US, LLC for the supply of Migalastat (Galafold 123 mg), an FDA-approved enzyme replacement therapy for the treatment of Fabry disease. This firm fixed-price delivery order, awarded on March 13, 2026, with an ultimate completion date of April 13, 2026, represents one of over 150 task orders placed under Amicus Therapeutics' parent Federal Supply Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB). The award carries no set-aside designation and will be performed in Philadelphia, Pennsylvania.
This delivery order exemplifies the VA's ongoing commitment to providing specialized pharmaceutical treatments to veterans with rare genetic diseases. Amicus Therapeutics US, LLC serves as the sole prime contractor under the parent FSS-61-IB contract (valued at $13.0 million, effective through August 31, 2029), which has enabled multiple Veterans Integrated Service Networks across the country to procure critical medications for Fabry disease management. The company maintains a consistent pattern of direct performance without subcontractor involvement, ensuring supply chain control for this essential specialized medication. Many of these procurement activities are expedited to accommodate emergency pharmacy purchases, underscoring the clinical urgency of maintaining adequate supplies of this rare disease treatment within the Veterans Health Administration.
Quick answers
Who was awarded contract 36C26126F0156?
36C26126F0156 was awarded to Amicus Therapeutics US, LLC by Veterans Integrated Service Network 21 (Veterans Health Administration) on March 13, 2026.
How much is contract 36C26126F0156 worth?
The government has obligated $22,840 on 36C26126F0156.
Is contract 36C26126F0156 an order under another contract?
Yes. 36C26126F0156 is a delivery order under 36F79724D0185, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C26126F0156 competed?
The extent of competition for 36C26126F0156 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award